Memorial Sloan Kettering Cancer Center’s CEO on the Future of Cancer Treatment

9 snips

Oct 7, 2025

Dr. Selwyn M. Vickers, President and CEO of Memorial Sloan Kettering Cancer Center, delves into pioneering advancements in cancer care. He explores the groundbreaking potential of targeted therapies and immunotherapy during this 'golden era' of treatment. Vickers discusses innovative approaches to pancreatic cancer, including promising vaccine trials. He also addresses rising cancer rates in younger populations and emphasizes the importance of health equity. Listeners gain valuable prevention tips and a sense of hope for the future of oncology.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

ADVICE

Make Tumor Sequencing Routine

Sequence tumors routinely to identify druggable driver mutations and personalize treatment choices.
Use computational oncologists to turn raw genomic numbers into clinically actionable targets.

INSIGHT

Precision, Immunotherapy And Computation Unite

Precision oncology finds actionable targets in nearly half of tumors and changes treatment choices.
Combining targeted drugs, immunotherapy, and computational biology defines today's 'golden era' of cancer care.

ANECDOTE

From Coley's Toxin To CAR‑T Cells

William Coley's 19th-century observations linked infections to anti-cancer immune responses.
CAR-T built on immune principles by re-engineering patients' cells to target and kill cancer.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Memorial Sloan Kettering Cancer Center is a world-renowned institution dedicated to cancer care, research, and education. CEO and president Selwyn M. Vickers, MD, FACS, discusses the latest advancements in cancer treatment, including targeted therapies, immunotherapy, and AI. He shares insights on the "golden era” of cancer treatment and the potential for improved patient outcomes.

This episode was recorded on July 30, 2025.

The opinions and views expressed herein are as of the date of publication, subject to change without notice, and may not necessarily reflect the institutional views of Goldman Sachs or its affiliates. The material provided is intended for informational purposes only, and does not constitute investment advice, a recommendation from any Goldman Sachs entity to take any particular action, or an offer or solicitation to purchase or sell any securities or financial products. This material may contain forward-looking statements. Past performance is not indicative of future results. Neither Goldman Sachs nor any of its affiliates make any representations or warranties, express or implied, as to the accuracy or completeness of the statements or information contained herein and disclaim any liability whatsoever for reliance on such information for any purpose. Each name of a third-party organization mentioned is the property of the company to which it relates, is used here strictly for informational and identification purposes only and is not used to imply any ownership or license rights between any such company and Goldman Sachs.

A transcript is provided for convenience and may differ from the original video or audio content. Goldman Sachs is not responsible for any errors in the transcript. This material should not be copied, distributed, published, or reproduced in whole or in part or disclosed by any recipient to any other person without the express written consent of Goldman Sachs.

Learn more about your ad choices. Visit megaphone.fm/adchoices